Full Text View
Tabular View
No Study Results Posted
Related Studies
A Comparison of Seroquel Vs. Risperidone in Schizophrenia
This study has been completed.
First Received: May 2, 2002   Last Updated: June 23, 2005   History of Changes
Sponsor: AstraZeneca
Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00034905
  Purpose

The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.


Condition Intervention Phase
Schizophrenia
Drug: quetiapine fumarate vs risperidone
Phase IV

Study Type: Interventional
Study Design: Treatment

Resource links provided by NLM:

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Male / Female, 18-65 years old
  • Schizophrenia (as per DSM IV)

Exclusion Criteria

  • Concurrent use of psychotropic medication
  • Does not fulfill moderately ill on CGI
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00034905

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
United States, California
Chula Vista, California, United States
Glendale, California, United States
Long Beach, California, United States
Torrance, California, United States
Anaheim, California, United States
Hawthorne, California, United States
Cerritos, California, United States
San Diego, California, United States
Santa Ana, California, United States
United States, Connecticut
New Haven, Connecticut, United States
Farmington, Connecticut, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Miami Beach, Florida, United States
Winter Park, Florida, United States
North Miami, Florida, United States
Miami, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Illinois
Hoffman Estates, Illinois, United States
United States, Kansas
Wichita, Kansas, United States
Prairie Village, Kansas, United States
United States, Louisiana
Shreveport, Louisiana, United States
New Orleans, Louisiana, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Worcester, Massachusetts, United States
Boston, Massachusetts, United States
United States, Michigan
New Baltimore, Michigan, United States
Ann Arbor, Michigan, United States
United States, Missouri
St. Louis, Missouri, United States
Kansas City, Missouri, United States
United States, Nevada
Reno, Nevada, United States
United States, New Jersey
Clementon, New Jersey, United States
Summit, New Jersey, United States
Lyons, New Jersey, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
White Plains, New York, United States
Montrose, New York, United States
Holliswood, New York, United States
New York, New York, United States
Oceanside, New York, United States
Bronx, New York, United States
United States, North Carolina
Butner, North Carolina, United States
United States, Ohio
Beachwood, Ohio, United States
Columbus, Ohio, United States
Cincinnati, Ohio, United States
Chagrin Falls, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Media, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, Tennessee
Memphis, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Terrell, Texas, United States
Waco, Texas, United States
Austin, Texas, United States
Houston, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
Falls Church, Virginia, United States
Richmond, Virginia, United States
Virginia Beach, Virginia, United States
United States, Washington
Vancouver, Washington, United States
Kirkland, Washington, United States
Tacoma, Washington, United States
United States, Wisconsin
West Allis, Wisconsin, United States
Sponsors and Collaborators
AstraZeneca
  More Information

No publications provided

Study ID Numbers: 5077US/0043
Study First Received: May 2, 2002
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00034905     History of Changes
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Risperidone
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Pharmacologic Actions
Schizophrenia
Quetiapine
Serotonin Antagonists
Serotonin Agents
Mental Disorders
Therapeutic Uses
Dopamine Agents
Central Nervous System Agents
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on November 22, 2009